ArticlePloS one2026
Prevalence, perceptions and factors associated with non-adherence to hepatotoxicity monitoring among people living with HIV on tuberculosis preventive treatment at Mulago ISS clinic.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatotoxicity monitoring is recommended for people living with HIV (PLHIV) enrolled on tuberculosis preventive treatment (TPT). Despite a 7.3% hepatotoxicity incidence reported in a multi-country study, implementation and adherence to hepatotoxicity monitoring remains low. We aimed at determining the prevalence, patients' and health workers' perceptions, and factors associated with non-adherence to hepatotoxicity monitoring among adult PLHIV receiving TPT at Mulago ISS clinic.
methodsA sequential explanatory mixed methods study was carried among health workers and adult PLHIV enrolled on TPT between 2022 and 2023 at Mulago ISS clinic. The quantitative and qualitative components utilized a cross-sectional and an exploratory descriptive design respectively. A data abstraction tool was used to obtain quantitative data from files and electronic medical records of a systematic random sample of 390 patients. The qualitative study utilized interview guides to conduct in-depth audio recorded interviews for five patients and five health workers. Descriptive statistics and modified Poisson regression analyses were performed for the quantitative data. Deductive thematic analysis based on the health belief model was utilized for the qualitative data.
resultsThe prevalence of non-adherence to hepatotoxicity monitoring was 87.4% (95%CI: 83.7-90.4). The prevalence of non-adherence to hepatotoxicity monitoring was 85% lower in PLHIV that received primary TPT as compared to those on secondary TPT (aPR-0.15, 95% CI: 0.04-0.55). The qualitative findings revealed varied perceptions about non-adherence to hepatotoxicity monitoring that included awareness of associated risks, perceived benefits of monitoring, and confidence in taking action, while also identifying perceived barriers such as financial, knowledge and communication challenges.
conclusionsThe prevalence of non-adherence to hepatotoxicity monitoring was high within this pharmacovigilance sentinel site, given its clinical importance in HIV care and clear recommendations in the national HIV treatment guidelines. Health authorities should implement policies promoting hepatotoxicity monitoring in pharmacovigilance sentinel sites, especially for patients receiving secondary TPT, and allocate resources to support this initiative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.